(furfuryl)(3-methyl-2,4,8,9-tetrazabicyclo[4.3.0]nona-1,3,5,7-tetraen-5-yl)amine | 5326-75-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并嘧啶类
• 英文名称: (furfuryl)(3-methyl-2,4,8,9-tetrazabicyclo[4.3.0]nona-1,3,5,7-tetraen-5-yl)amine
• 英文别名: furfuryl-(6-methyl-1(2)H-pyrazolo[3,4-d]pyrimidin-4-yl)-amine；NoName_4231；N-(furan-2-ylmethyl)-6-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine
• CAS: 5326-75-0
• 化学式: C₁₁H₁₁N₅O
• 分子量: 229.241
• InChiKey: JFTBZRLPFLOMHC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  79.6
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
  申请人：Mitokinin, LLC

  公开号：US10167286B2

  公开（公告）日：2019-01-01

  The disclosure is directed to compounds and pharmaceutically acceptable salts thereof for the treatment and/or prevention of neurodegenerative and/or mitochondrial diseases, such as Parkinson's disease and Leigh's disease. The compounds and pharmaceutically acceptable salts thereof are of the class of nitrogenous bases, for example, pyrimidines, purines, pteridines and pharmaceutically acceptable salts thereof.

  本公开涉及用于治疗和/或预防神经退行性疾病和/或线粒体疾病（如帕金森病和利氏病）的化合物及其药学上可接受的盐。这些化合物及其药学上可接受的盐属于含氮碱类，例如嘧啶、嘌呤、蝶啶及其药学上可接受的盐。
• Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease
  申请人：Mitokinin, Inc.

  公开号：US10851109B2

  公开（公告）日：2020-12-01

  The disclosure is directed to compounds and pharmaceutically acceptable salts thereof for the treatment and/or prevention of neurodegenerative and/or mitochondrial diseases, such as Parkinson's disease and Leigh's disease. The compounds and pharmaceutically acceptable salts thereof are of the class of nitrogenous bases, for example, pyrimidines, purines, pteridines, and pharmaceutically acceptable salts thereof.

  本公开涉及用于治疗和/或预防神经退行性疾病和/或线粒体疾病（如帕金森病和利氏病）的化合物及其药学上可接受的盐。这些化合物及其药学上可接受的盐属于含氮碱类，例如嘧啶、嘌呤、蝶啶及其药学上可接受的盐。
• COMPOSITIONS AND METHODS USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE
  申请人：Mitokinin, LLC

  公开号：US20170190704A1

  公开（公告）日：2017-07-06

  The present disclosure is directed, in part, to compounds, or pharmaceutically acceptable salts thereof, for the treatment and/or prevention of neurodegenerative disease and/or mitchonodrial disease including Parkinson's disease and Leigh's disease.
• COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE
  申请人：Mitokinin, Inc.

  公开号：US20190194207A1

  公开（公告）日：2019-06-27

  The present disclosure is directed, in part, to compounds, or pharmaceutically acceptable salts thereof, for the treatment and/or prevention of neurodegenerative disease, mitochondrial disease, fibrosis, and/or cardiomyopathy.
• Compositions and Methods of Using the Same for Treatment of Neurodegenerative and Mitochondrial Disease
  申请人：Mitokinin, Inc.

  公开号：US20210107910A1

  公开（公告）日：2021-04-15

  The disclosure is directed to compounds and pharmaceutically acceptable salts thereof for the treatment and/or prevention of neurodegenerative and/or mitochondrial diseases, such as Parkinson's disease and Leigh's disease. The compounds and pharmaceutically acceptable salts thereof are of the class of nitrogenous bases, for example, pyrimidines, purines, pteridines, and pharmaceutically acceptable salts thereof.